newsfilter
← Latest News
GlobeNewswire·

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases,